ZA200902453B - PAI-1 binding modulators for the treatment of ocular disorders - Google Patents
PAI-1 binding modulators for the treatment of ocular disordersInfo
- Publication number
- ZA200902453B ZA200902453B ZA200902453A ZA200902453A ZA200902453B ZA 200902453 B ZA200902453 B ZA 200902453B ZA 200902453 A ZA200902453 A ZA 200902453A ZA 200902453 A ZA200902453 A ZA 200902453A ZA 200902453 B ZA200902453 B ZA 200902453B
- Authority
- ZA
- South Africa
- Prior art keywords
- pai
- treatment
- ocular disorders
- binding modulators
- modulators
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86371506P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200902453B true ZA200902453B (en) | 2010-07-28 |
Family
ID=39345074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200902453A ZA200902453B (en) | 2006-10-31 | 2007-10-31 | PAI-1 binding modulators for the treatment of ocular disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080107644A1 (enExample) |
| EP (1) | EP2077829A2 (enExample) |
| JP (1) | JP2010508306A (enExample) |
| KR (1) | KR20090082401A (enExample) |
| CN (1) | CN101588798A (enExample) |
| AU (1) | AU2007313684A1 (enExample) |
| CA (1) | CA2666316A1 (enExample) |
| MX (1) | MX2009004792A (enExample) |
| RU (1) | RU2465898C2 (enExample) |
| WO (1) | WO2008055205A2 (enExample) |
| ZA (1) | ZA200902453B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| US20100158897A1 (en) * | 2006-10-31 | 2010-06-24 | Alcon Research, Ltd. | Pai-1 modulators for the treatment of ocular disorders |
| JP5924625B2 (ja) * | 2011-11-15 | 2016-05-25 | 国立大学法人浜松医科大学 | プラスミノゲンアクチベータインヒビター−１による流産、早産治療薬 |
| US10946076B2 (en) | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
| US9820954B2 (en) * | 2015-08-19 | 2017-11-21 | Jenivision Inc. | Quantitative peri-orbital application of ophthalmology drugs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9306399A (pt) * | 1992-05-22 | 1998-09-15 | Senju Pharma Co | Composição farmacéutica para uso no tratamento de glaucoma |
| AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| EA004050B1 (ru) * | 1998-12-11 | 2003-12-25 | Бакулиш Мафатлал Хамар | Способ изготовления состава местных бета-блокаторов улучшенного действия |
| AU771635B2 (en) * | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| CA2476761A1 (en) * | 2002-02-19 | 2003-08-28 | Vanderbilt University | Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors |
| EP1497420A4 (en) * | 2002-04-30 | 2005-04-27 | Alcon Inc | AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES |
-
2007
- 2007-10-31 US US11/931,393 patent/US20080107644A1/en not_active Abandoned
- 2007-10-31 CA CA002666316A patent/CA2666316A1/en not_active Abandoned
- 2007-10-31 EP EP07868631A patent/EP2077829A2/en not_active Withdrawn
- 2007-10-31 RU RU2009120545/15A patent/RU2465898C2/ru not_active IP Right Cessation
- 2007-10-31 WO PCT/US2007/083170 patent/WO2008055205A2/en not_active Ceased
- 2007-10-31 MX MX2009004792A patent/MX2009004792A/es not_active Application Discontinuation
- 2007-10-31 AU AU2007313684A patent/AU2007313684A1/en not_active Abandoned
- 2007-10-31 KR KR1020097010021A patent/KR20090082401A/ko not_active Withdrawn
- 2007-10-31 ZA ZA200902453A patent/ZA200902453B/xx unknown
- 2007-10-31 CN CNA2007800407976A patent/CN101588798A/zh active Pending
- 2007-10-31 JP JP2009534946A patent/JP2010508306A/ja active Pending
-
2010
- 2010-06-25 US US12/823,773 patent/US20100260784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2465898C2 (ru) | 2012-11-10 |
| US20080107644A1 (en) | 2008-05-08 |
| MX2009004792A (es) | 2009-05-21 |
| WO2008055205A2 (en) | 2008-05-08 |
| EP2077829A2 (en) | 2009-07-15 |
| RU2009120545A (ru) | 2010-12-10 |
| CA2666316A1 (en) | 2008-05-08 |
| AU2007313684A1 (en) | 2008-05-08 |
| CN101588798A (zh) | 2009-11-25 |
| KR20090082401A (ko) | 2009-07-30 |
| JP2010508306A (ja) | 2010-03-18 |
| WO2008055205A3 (en) | 2008-07-17 |
| US20100260784A1 (en) | 2010-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL191283A (en) | Compositions for treating eye irregularities | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| IL193747A0 (en) | New therapeutic combinations for the treatment of depression | |
| IL188204A0 (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| ZA200900734B (en) | Combination treatment for metabolic disorders | |
| IL195819A0 (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| ZA200900055B (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| IL193936A0 (en) | Compositions and methods for the treatment of immunoinflammatory disorders | |
| ZA200808963B (en) | Compounds for the treatment of metabolic disorders | |
| IL192852A0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| IL193799A0 (en) | New therapeutic combinations for the treatment or prevention of psycotic disorders | |
| IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
| IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
| IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL192982A0 (en) | Compounds for the treatment of metabolic disorders | |
| HK1121947A (en) | Gdf-9/bmp-15 modulators for the treatment of bone disorders | |
| GB0608007D0 (en) | Preparation for the treatment of burns | |
| HK1121736A (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| HK1122813A (en) | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto | |
| GB0724947D0 (en) | Composition for the treatment of psychiatric disorders | |
| HK1124246A (en) | Compounds for the treatment of metabolic disorders |